Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2000-08-03
2004-05-11
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S071100, C435S071200, C435S252300, C435S254110, C435S325000, C435S471000, C435S320100, C536S023500, C530S350000
Reexamination Certificate
active
06733990
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to novel GPCR-like nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
BACKGROUND OF THE INVENTION
G-protein coupled receptors (GPCRs) constitute a major class of proteins responsible for transducing a signal within a cell (Strosberg (1991)
Eur. J. Biochem
. 196:1-10; Kerlavage (1991)
Curr. Opin. Struct. Biol
. 1:394-401; Probst et al. (1992)
DNA Cell Biol
. 11:1-20; Savarese et al. (1992)
Biochem
283:1-9). GPCRs have three structural domains: an amino terminal extracellular domain; a transmembrane domain containing seven transmembrane segments, three extracellular loops, and three intracellular loops; and a carboxy terminal intracellular domain. Upon binding of a ligand to an extracellular portion of a GPCR, a signal is transduced within the cell that results in a change in a biological or physiological property of the cell. GPCRs, along with G-proteins and effectors (intracellular enzymes and channels modulated by G-proteins), are the components of a modular signaling system that connects the state of intracellular second messengers to extracellular inputs.
GPCR genes and gene-products are potential causative agents of disease (Spiegel et al. (1993)
J. Clin. Invest
. 92:1119-1125; McKusick et al. (1993)
J. Med. Genet
. 30:1-26). Specific defects in the rhodopsin gene and the V2 vasopressin receptor gene have been shown to cause various forms of retinitis pigmentosum (Nathans et al. (1992)
Annu. Rev. Genet
. 26:403-424) and nephrogenic diabetes insipidus (Holtzman et al. (1993)
Hum. Mol. Genet
. 2:1201-1204). These receptors are of critical importance to both the central nervous system and peripheral physiological processes. Evolutionary analyses suggest that the ancestor of these proteins originally developed in concert with complex body plans and nervous systems.
In addition to variability among individuals in their responses to drugs, several definable diseases arise from disorders of receptor function or receptor-effector systems. The loss of a receptor in a highly specialized signaling system may cause a relatively limited phenotypic disorder, such as the genetic deficiency of the androgen receptor in the testicular feminization syndrome (Griffin et al. (1995)
The Metabolic and Molecular Bases of Inherited Diseases
7:2967-2998). Deficiencies of more widely used signaling systems have a broader spectrum of effects, as are seen in myasthenia gravis or some forms of insulin-resistant diabetes mellitus, which result from autoimmune depletion of nicotinic cholinergic receptors or insulin receptors, respectively. A lesion in a component of a signaling pathway that is used by many receptors can cause a generalized endocrinopathy. Heterozygous deficiency in G
5
, the G protein that activates adenylyl cyclase in all cells, causes multiple endocrine disorders; the disease is termed
pseudohpoparathyroidism type
1
a
(Spiegel et al. (1995)
The Metabolic and Molecular Bases of Inherited Diseases
7:3073-3089). Homozygous deficiency in G
5
would presumably be lethal.
The expression of aberrant or ectopic receptors, effectors, or coupling proteins potentially can lead to supersensitivity, subsensitivity, or other untoward responses. Among the most interesting and significant events is the appearance of aberrant receptors as products of oncogenes, which transform otherwise normal cells into malignant cells. Virtually any type of signaling system may have oncogenic potential. G proteins can themselves be oncogenic when either overexpressed or constitutively activated by mutation (Lyons et al (1990)
Science
249:655-659). In particular, the calcitonin receptor is a target for treatment of Paget's disease of the bone; the receptor for glucagon-like peptide 1 is a target for non-insulin dependent diabetes mellitus; parathyroid hormone is involved in calcium homeostasis. Antagonists of the parathyroid hormone receptor are of potential clinical use in the treatment of hyperparathyroidism and short-term hypercalcemic states.
The GPCR protein superfamily can be divided into five families: Family I, receptors typified by rhodopsin and the &bgr;2-adrenergic receptor and currently represented by over 200 unique members (Dohlman et al. (1991)
Annu. Rev. Biochem
. 60:653-688); Family II, the parathyroid hormone/calcitonin/secretin receptor family/Class B Secretin-like Family (Juppner et al. (1991)
Science
254:1024-1026; Lin et al. (1991)
Science
254:1022-1024); Family III, the metabotropic glutamate receptor family (Nakanishi (1992)
Science
258 597:603); Family IV, the cAMP receptor family, important in the chemotaxis and development of
D. discoideum
(Klein et al. (1988)
Science
241:1467-1472); and Family V, the fungal mating pheromone receptors such as STE2 (Kwjan (1992)
Annu. Rev. Biochem
. 61:1097-1129).
G proteins represent a family of heterotrimeric proteins composed of &agr;, &bgr;, and &ggr; subunits that bind guanine nucleotides. These proteins are usually linked to cell surface receptors, e.g., receptors containing seven transmembrane segments. Following ligand binding to the GPCR, a conformational change is transmitted to the G protein, which causes the &agr;-subunit to exchange a bound GDP molecule for a GTP molecule and to dissociate from the &bgr;&ggr;-subunits. The GTP-bound form of the &agr;-subunit typically functions as an effector-modulating moiety, leading to the production of second messengers, such as cAMP (e.g., by activation of adenyl cyclase), diacylglycerol or inositol phosphates. Greater than different types of &agr;-subunits are known in humans. These subunits associate with a smaller pool of &bgr; and &ggr; subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs, and Gt. G proteins are described extensively in Lodish et al.(1995)
Molecular Cell Biology
(Scientific American Books Inc., New York, N.Y.), the contents of which are incorporated herein by reference. GPCRs, G proteins and G protein-linked effector and second messenger systems have been reviewed in Watson et al., eds. (1994)
The G-Protein Linked Receptor Fact Book
(Academic. Press, NY).
GPCRs are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown GPCRs. The present invention advances the state of the art by providing previously unidentified human GPCR-like sequences.
SUMMARY OF THE INVENTION
Isolated nucleic acid molecules corresponding to GPCR-like nucleic acid sequences are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2 or the nucleotide sequence encoding the DNA sequence deposited in a bacterial host with ATCC as Accession Number PTA-1660. Further provided are GPCR-like polypeptides having an amino acid sequence encoded by a nucleic acid molecule described herein, such as the sequence shown in SEQ ID NO:1.
The present invention also provides vectors and host cells for recombinant expression of the nucleic acid molecules described herein, as well as methods of making such vectors and host cells and for using them for production of the polypeptides or peptides of the invention by recombinant techniques.
The GPCR-like molecules of the present invention find use in identifying compounds that act as agonists and antagonists and modulate the expression of the novel receptors. Furthermore, compounds that modulate expression of the receptors for treatment and diagnosis of GPCR-related disorders are also encompassed. The molecules are useful for the treatment of immune, hematologic, fibrotic, hepatic, and respiratory disorders, including, but not limited to, atopic conditions, such as asthma and allergy, including allergic rhinitis, psoriasis, the effects of pathogen infection, chronic inflammatory diseases, o
Hodge Martin R.
Lloyd Clare
Weich Nadine S.
Mertz Prema
Millennium Pharmaceuticals Inc.
Millennium Pharmaceuticals Inc.
LandOfFree
Nucleic acid encoding 15571, a GPCR-like molecule of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid encoding 15571, a GPCR-like molecule of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid encoding 15571, a GPCR-like molecule of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3205667